Australia markets closed
  • ALL ORDS

    7,709.50
    +21.50 (+0.28%)
     
  • ASX 200

    7,493.80
    +25.50 (+0.34%)
     
  • AUD/USD

    0.7110
    -0.0007 (-0.10%)
     
  • OIL

    79.38
    -1.63 (-2.01%)
     
  • GOLD

    1,927.60
    -2.40 (-0.12%)
     
  • BTC-AUD

    32,301.61
    +194.56 (+0.61%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • AUD/EUR

    0.6538
    +0.0009 (+0.14%)
     
  • AUD/NZD

    1.0934
    -0.0026 (-0.24%)
     
  • NZX 50

    12,036.05
    +12.59 (+0.10%)
     
  • NASDAQ

    12,166.60
    +115.12 (+0.96%)
     
  • FTSE

    7,765.15
    +4.04 (+0.05%)
     
  • Dow Jones

    33,978.08
    +28.67 (+0.08%)
     
  • DAX

    15,150.03
    +17.18 (+0.11%)
     
  • Hang Seng

    22,688.90
    +122.12 (+0.54%)
     
  • NIKKEI 225

    27,382.56
    +19.81 (+0.07%)
     

Ultralife Corporation Reports Third Quarter Results

Ultralife Corporation
Ultralife Corporation

NEWARK, N.Y., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $0.6 million and adjusted EBITDA of $1.3 million on revenue of $33.2 million for the third quarter ended September 30, 2022. For the third quarter of 2021, the Company reported an operating loss of $0.8 million and adjusted EBITDA of $0.3 million on revenue of $21.8 million.

“For the third quarter, government/defense revenue doubled year-over-year reflecting higher demand from our customers in Battery & Energy Products and shipments of larger awards in Communications Systems. This increase in government/defense revenue along with the addition of Excell, resulted in a 53% increase in total Company revenue. While we benefited from the operating expense leverage of the sharp revenue gain, the combination of production inefficiencies associated with supply chain disruptions and input cost inflation severely pressured gross margins and profitability for the quarter,” said Michael D. Popielec, President and Chief Executive Officer. “We continue to work on offsetting inflation and manufacturing workflow challenges with price realization and productivity gains to restore profitable growth. With a backlog now over $100 million, we are positioned well for near-term revenue increases and remain committed to advancing several transformational projects and new product opportunities to drive long-term revenue growth.”

Third Quarter 2022 Financial Results

Revenue was $33.2 million, an increase of $11.5 million, or 52.7%, compared to $21.8 million for the third quarter of 2021. Overall, government/defense sales increased 99.8% and commercial sales increased 38.0% from the 2021 period. Battery & Energy Products revenue increased 42.9% to $28.6 million, compared to $20.0 million last year, reflecting $6.9 million of Excell sales coupled with organic increases of 66.4% in government/defense sales, 7.4% in oil & gas market sales and 2.4% in industrial market sales, partially offset by a 12.1% decrease in medical sales. Net organic sales for this segment increased 8.5%. Communications Systems sales increased 165.3% to $4.7 million compared to $1.8 million for the same period last year, despite lingering supply chain disruptions resulting in delays in our shipments to future periods.   Our total backlog exiting the third quarter grew to $106.2 million, which represents an increase of $27.0 million or 34.1% over the comparable backlog exiting the prior quarter and an increase of $64.2 million or 153.3% over that exiting the third quarter of 2021.

Gross profit was $6.7 million, or 20.2% of revenue, compared to $5.1 million, or 23.5% of revenue, for the same quarter a year ago.   Battery & Energy Products’ gross margin was 18.7% compared to 24.0% last year, primarily due to supply chain disruptions including component cost inflation, prolonged lead times and logistics delays, and the incremental costs of transitioning new products to high volume production. Communications Systems gross margin was 29.5% compared to 18.0% last year, primarily due to higher factory volume and more favorable sales mix.

Operating expenses were $7.3 million compared to $5.9 million last year, an increase of 24.0% , reflecting $1.1 million for Excell. Operating expense ratio to revenue was 22.0%, a 510 basis-point improvement as compared to 27.1% of revenue for the year-earlier period.

Operating loss was $0.6 million compared to $0.8 million last year.

Net loss was $0.2 million or $0.01 per diluted share on a GAAP basis compared to a net loss of $0.6 million or $0.04 per diluted share for the third quarter of 2021.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $1.3 million or 3.8% of sales for the third quarter of 2022, compared to $0.3 million or 1.3% of sales for the year-earlier period.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of Adjusted EPS to EPS and adjusted EBITDA to net (loss) income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its third quarter earnings conference call today at 8:30 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include the impact of COVID-19 and related supply chain disruptions, potential reductions in revenues from key customers, acceptance of our new products on a global basis and uncertain global economic conditions. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

Company Contact: 

Investor Relations Contact:

Ultralife Corporation

LHA

Philip A. Fain  

Jody Burfening

(315) 210-6110

(212) 838-3777

pfain@ulbi.com

jburfening@lhai.com


ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands)

(Unaudited)



ASSETS

 

 

 

 

                                                                

September 30,
2022

 

December 31,
2021

Current Assets:

 

 

 

Cash

$5,051

 

$8,413

Trade Accounts Receivable, Net

26,876

 

20,232

Inventories, Net

40,769

 

33,189

Prepaid Expenses and Other Current Assets

6,241

 

4,690

Total Current Assets

78,937

 

66,524

 

 

 

 

Property, Plant and Equipment, Net

21,898

 

23,205

Goodwill

37,066

 

38,068

Other Intangible Assets, Net

16,095

 

17,390

Deferred Income Taxes, Net

11,963

 

11,472

Other Non-Current Assets

1,981

 

2,879



           Total Assets

$167,940

 

$159,538

     

LIABILITIES AND SHAREHOLDERS' EQUITY



Current Liabilities:

  

 

Accounts Payable

$15,827

 

$9,823

Current Portion of Long-Term Debt

2,000

 

2,000

Accrued Compensation and Related Benefits

2,000

 

1,842

Accrued Expenses and Other Current Liabilities

8,254

 

5,259

Total Current Liabilities

28,081

 

18,924

Long-Term Debt, Net

20,874

 

18,857

Deferred Income Taxes

1,996

 

2,254

Other Non-Current Liabilities

1,673

 

1,760

Total Liabilities

52,624

 

41,795

 

 

 

 

Shareholders' Equity:

 

 

 

Common Stock

2,057

 

2,052

Capital in Excess of Par Value

187,181

 

186,518

Accumulated Deficit

(47,727)

 

(47,832)

Accumulated Other Comprehensive Loss

(4,842)

 

(1,653)

Treasury Stock

(21,480)

 

(21,469)

Total Ultralife Equity

115,189

 

117,616

Non-Controlling Interest

127

 

127

Total Shareholders’ Equity

115,316

 

117,743

 

 

 

 

Total Liabilities and Shareholders' Equity

$167,940

 

$159,538

                                                                        

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF (LOSS) INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

 

 

 

 

 

 

 

 

Three-Month Period Ended

 

Nine-Month Period Ended

 

September 30,

 

September 30,

 

September 30,

 

September 30,

 

2022

 

2021

 

2022

 

2021

Revenues:

 

 

 

 

 

 

 

Battery & Energy Products

$28,583

 

$20,008

 

$87,873

 

$64,994

Communications Systems

4,651

 

1,753

 

7,860

 

9,510

Total Revenues

33,234

 

21,761

 

95,733

 

74,504

 

 

 

 

 

 

 

 

Cost of Products Sold:

 

 

 

 

 

 

 

Battery & Energy Products

23,238

 

15,216

 

68,656

 

48,750

Communications Systems

3,281

 

1,437

 

5,758

 

6,401

Total Cost of Products Sold

26,519

 

16,653

 

74,414

 

55,151

 

 

 

 

 

 

 

 

Gross Profit

6,715

 

5,108

 

21,319

 

19,353

 

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

Research and Development

1,896

 

1,723

 

5,425

 

5,223

Selling, General and Administrative

5,405

 

4,164

 

15,982

 

12,866

Total Operating Expenses

7,301

 

5,887

 

21,407

 

18,089

 

 

 

 

 

 

 

 

Operating (Loss) Income

(586)

 

(779)

 

(88)

 

1,264

 

 

 

 

 

 

 

 

Other (Income) Expense

(254)

 

(1)

 

(22)

 

76

(Loss) Income Before Income Taxes

(332)

 

(778)

 

(66)

 

1,188

 

 

 

 

 

 

 

 

Income Tax (Benefit) Provision

(90)

 

(175)

 

(171)

 

290

 

 

 

 

 

 

 

 

Net (Loss) Income

(242)

 

(603)

 

105

 

898

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Non-Controlling Interest

(3)

 

(18)

 

-

 

1

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Ultralife Corporation

($239)

 

($585)

 

$105

 

$897

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Basic

($.01)

 

($.04)

 

$.01

 

$.06

 

 

 

 

 

 

 

 

Net (Loss) Income Per Share Attributable to Ultralife Common Shareholders – Diluted

($.01)

 

($.04)

 

$.01

 

$.06

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Basic

16,133

 

16,065

 

16,122

 

16,020

 

 

 

 

 

 

 

 

Weighted Average Shares Outstanding – Diluted

16,133

 

16,065

 

16,144

 

16,200


Non-GAAP Financial Measures:

Adjusted EBITDA

In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income (loss) attributable to Ultralife Corporation before net interest expense, provision (benefit) for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income (loss) attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

ULTRALIFE CORPORATION AND SUBSIDIARIES

CALCULATION OF ADJUSTED EBITDA

(Dollars in Thousands)

(Unaudited)


 

Three-Month Period Ended

 

Nine-Month Period Ended

 

September 30, 2022

 

September 30, 2021

 

September 30, 2022

 

September 30, 2021

 

 

 

 

 

 

 

 

Net (Loss) Income Attributable to Ultralife Corporation

($239)

 

($585)

 

$105

 

$897

Adjustments:

 

 

 

 

 

 

 

Interest and Financing Expense

272

 

53

 

583

 

164

Income Tax (Benefit) Provision

(90)

 

(175)

 

(171)

 

290

Depreciation Expense

815

 

700

 

2,450

 

2,160

Amortization Expense

318

 

148

 

969

 

458

Stock-Based Compensation Expense

179

 

142

 

552

 

512

Non-Cash Purchase Accounting Adjustment

-

 

-

 

55

 

-

Adjusted EBITDA

$1,255

 

$283

 

$4,543

 

$4,481